Therapeutic Assessment of Primaquine for Radical Cure of Plasmodium vivax Malaria at Primary and Tertiary Care Centres in Southwestern India
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Acquaintance is scanty on primaquine (PQ) efficacy and Plasmodium vivax recurrence in Udupi district, Karnataka, India. We assessed the efficacy of 14 days PQ regimen (0.25 mg/kg/day) to prevent P. vivax recurrence. Microscopically, aparasitemic adults (≥18 years) after acute vivax malaria on day 28 were re-enrolled into 15 months’ long follow-up study. A peripheral blood smear examination was performed with participants at every 1-2 month interval. A nested PCR test was performed to confirm the mono-infection with P. vivax. Of 114 participants, 28 (24.6%) recurred subsequently. The median (IQR) duration of the first recurrence was 3.1 (2.2-5.8) months which ranged from 1.2 to 15.1 months, including initial 28 days. Participants with history of vivax malaria had significantly higher risk of recurrence, with hazard ratio (HR) (95% CI) of 2.62 (1.24-5.54) (P=0.012). Severity of disease (11.4%, 13/114) was not associated (P=1.00) with recurrence. Of 28 recurrence cases, the nPCR proved that P. vivax mono-infection recurrence rate was at least 72.7% (16/22) at first recurrence. In Udupi district, PQ dose of 0.25 mg/kg/day over 14 days seems inadequate to prevent recurrence in substantial proportion of vivax malaria. Patients with a history of vivax malaria are at high risk of recurrences.
Abstract
Acquaintance is scanty on primaquine (PQ) efficacy and Plasmodium vivax recurrence in Udupi district, Karnataka, India. We assessed the efficacy of 14 days PQ regimen (0.25 mg/kg/day) to prevent P. vivax recurrence. Microscopically, aparasitemic adults (≥18 years) after acute vivax malaria on day 28 were re-enrolled into 15 months’ long follow-up study. A peripheral blood smear examination was performed with participants at every 1-2 month interval. A nested PCR test was performed to confirm the mono-infection with P. vivax. Of 114 participants, 28 (24.6%) recurred subsequently. The median (IQR) duration of the first recurrence was 3.1 (2.2-5.8) months which ranged from 1.2 to 15.1 months, including initial 28 days. Participants with history of vivax malaria had significantly higher risk of recurrence, with hazard ratio (HR) (95% CI) of 2.62 (1.24-5.54) (P=0.012). Severity of disease (11.4%, 13/114) was not associated (P=1.00) with recurrence. Of 28 recurrence cases, the nPCR proved that P. vivax mono-infection recurrence rate was at least 72.7% (16/22) at first recurrence. In Udupi district, PQ dose of 0.25 mg/kg/day over 14 days seems inadequate to prevent recurrence in substantial proportion of vivax malaria. Patients with a history of vivax malaria are at high risk of recurrences.
참고문헌 (23)
- World Malaria Report 2013, "WHO", World Health Organization, ~ (2013)
- Rishikesh K, "Primaquine treatment and relapse in Plasmodium vivax malaria", Pathog Glob Health, 110, pp.1~8 (2016)
- White NJ, "Determinants of relapse periodicity in Plasmodium vivax malaria", Malar J, 10, pp.297~ (2011)
- World Malaria Report 2014, "WHO", World Health Organization, ~ (2014)
- Directorate of National Vector Borne Disease Control Programme, "National Drug Policy on Malaria. 22-Shamnath Marg, Delhi-110054: Directorate General of Health Services", Ministry of Health and Family Welfare, ~ (2013)
- Srivastava HC, "Studies on Plasmodium vivax relapse pattern in Kheda district, Gujarat", Indian J Malariol, 33, pp.173~179 (1996)
- Adak T, "Studies on the Plasmodium vivax relapse pattern in Delhi, India", Am J Trop Med Hyg, 59, pp.175~179 (1998)
- Adak T, "Plasmodium vivax polymorphism in a clinical drug trial", Clin Diagn Lab Immunol, 8, pp.891~894 (2001)
- Gogtay NJ, "Relapse pattern of Plasmodium vivax in Mumbai : a study of 283 cases of vivax malaria", J Assoc Physicians India, 48, pp.1085~1086 (2000)
- Kim JR, "Genotyping of Plasmodium vivax reveals both short and long latency relapse patterns in Kolkata", PLoS One, 7, pp.e39645~ (2012)
- Gogtay N, "Efficacies of 5-and-14-day primaquine regimens in the prevention of relapses in Plasmodium vivax infections", Ann Trop Med Parasitol, 93, pp.809~812 (1999)
- Sinha S, "Efficacy of 5 day radical treatment of primaquine in Plasmodium vivax cases at the BHEL Industrial Complex, Hardwar (UP)", Indian J Malariol, 26, pp.83~86 (1989)
- Rishikesh K, "Therapeutic assessment of chloroquine-primaquine combined regimen in adult cohort of Plasmodium vivax malaria from a tertiary care hospital in southwestern India", Malar J, 14, pp.310~ (2015)
- Saravu K, "Therapeutic assessment of chloroquine-primaquine combined regimen in adult cohort of Plasmodium vivax malaria from primary care centres in southwestern India", PLoS One, 11, pp.e0157666~ (2016)
- World Health Organization, "Point-of-care G6PD testing to support safe use of primaquine for the treatment of vivax malaria. WHO Evidence Review Group meeting report", Malaria Policy Advisory Committee Meeting (2015)
- Rishikesh K, "Surmised total leucocyte counts miscalculate the parasite index of Plasmodium vivax malaria patients of tertiary and primary care settings in South-Western India", Malar J, 14, pp.163~ (2015)
- World Health Organization, "A practical handbook--Management of severe malaria. 3rd ed", World Health Organization, ~ (2012)
- Snounou G, "High sensitivity of detection of human malaria parasites by the use of nested polymerase chain reaction", Mol Biochem Parasitol, 61, pp.315~320 (1993)
- Saravu K, "Risk factors and outcomes stratified by severity of acute kidney injury in malaria", PLoS One, 9, pp.e90419~ (2014)
- Saravu K, "Severity in Plasmodium vivax malaria claiming global vigilance and exploration-a tertiary care centre-based cohort study", Malar J, 13, pp.304~ (2014)
- Saravu K, "Determinants of mortality, intensive care requirement and prolonged hospitalization in malaria-a tertiary care hospital based cohort study from South-Western India", Malar J, 13, pp.370~ (2014)
- Doolan DL, "Acquired immunity to malaria", Clin Microbiol Rev, 22, pp.13~36 (2009)
- Rishikesh K, "Therapeutic assessment of chloroquine-primaquine combined regimen in adult cohort of Plasmodium vivax malaria from a tertiary care hospital in southwestern India", Malar J, 14, pp.310~ (2015)